NRAS and hepatocellular carcinoma: In addition, NRAS activating mutations, amplification or upregulation have been implicated in resistance to targeted therapies such as TKIs used in NB and other cancers, such as hepatocellular carcinoma (HCC), metastatic colorectal cancer and NSCLC74–77.